Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Cash from Financing Activities of $3.2 million for Q1 2026, down 95.1% year-over-year from $65.7 million in Q1 2025, and up 1646.63% quarter-over-quarter from -$208000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 95.1% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $194.6 million (up 195.37% YoY), while the FY2025 annual figure was $257.0 million, up 73758.91% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $3.2 million, up from -$208000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $232.2 million in Q4 2022, with the low at -$828000.0 in Q2 2022.
- The 5-year median for Cash from Financing Activities is $559500.0 (2023), against an average of $43.5 million.
- Peak annual rise in Cash from Financing Activities reached 239407.5% in 2025, while the deepest fall reached 289.09% in 2025.
- Amylyx Pharmaceuticals' Cash from Financing Activities stood at $232.2 million in 2022, then slumped by 99.9% to $230000.0 in 2023, then plunged by 52.17% to $110000.0 in 2024, then plunged by 289.09% to -$208000.0 in 2025, then surged by 1646.63% to $3.2 million in 2026.
- Business Quant data shows AMLX's Cash from Financing Activities at $3.2 million in Q1 2026, -$208000.0 in Q4 2025, and $191.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.29 Bn | 4.29 Bn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.48 Mn |
| Jun 30, 2026 | 1.48 Mn |
| Mar 31, 2026 | 3.22 Mn |
| Mar 31, 2026 | 3.22 Mn |
| Dec 31, 2025 | -208,000.00 |
| Dec 31, 2025 | -208,000.00 |
| Sep 30, 2025 | 191.61 Mn |
| Sep 30, 2025 | 191.61 Mn |
| Jun 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Mar 31, 2025 | 65.66 Mn |
| Mar 31, 2025 | 65.66 Mn |
| Dec 31, 2024 | 110,000.00 |
| Dec 31, 2024 | 110,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 131,000.00 |
| Mar 31, 2024 | 131,000.00 |